Research Finds No Impact of Fragmented Care on Survival in Retroperitoneal Sarcoma Patients

Recent research from Fox Chase Cancer Center indicates that receiving fragmented care—treatment at multiple healthcare facilities—does not negatively influence the survival outcomes for patients with retroperitoneal sarcoma, a rare and aggressive cancer. While patients treated at several facilities often experience longer delays from diagnosis to treatment and must travel greater distances, their overall survival rates remain comparable to those who receive care at a single institution.

Fragmented care has historically been associated with mixed outcomes in cancer treatment, depending on factors such as cancer type and the quality of coordination among providers. However, this new study, analyzing data from the National Cancer Database covering 4,976 patients treated between 2004 and 2020, suggests that the complexity of care coordination may not necessarily affect survival for retroperitoneal sarcoma.

Patients who underwent treatment at multiple facilities traveled on average 36 miles compared to 13 miles for those at a single center. Similarly, the time from diagnosis to treatment was longer in the fragmented care group (43 days versus 16 days). Despite these differences, survival rates showed no significant variation.

Lead researcher Dr. Denise Wong emphasized the importance of personalized patient-centered approaches when making referral decisions. "This study is a call for providers to carefully consider the individual needs of retroperitoneal sarcoma patients, especially when referrals are involved. Traveling to a specialized high-volume center might not always be necessary if it doesn't translate into better survival chances, and we need to weigh the logistical and emotional impacts on patients."

Given the rarity of retroperitoneal sarcoma—comprising less than 1% of adult cancers—treatment at high-volume centers, which perform more than 13 surgeries yearly, is generally associated with better outcomes. However, with fewer than ten such centers in the U.S., patients often face difficult decisions regarding care options.

The study was led by Dr. Anthony Villano and aims to inform clinical practice by highlighting that, although longer travel and treatment delays are common in fragmented care, they do not necessarily compromise patient survival. "Our findings suggest flexibility in treatment planning; the key is to tailor care to each patient's circumstances while ensuring they receive effective treatment," Dr. Wong added.

This research underscores the importance of individualized decision-making in cancer care, particularly for rare tumors, and encourages healthcare providers to consider all factors when coordinating multidisciplinary treatment approaches.

[Source: https://medicalxpress.com/news/2025-05-fragmented-affect-survival-outcomes-retroperitoneal.html]